Evidence map›Paper›PMID 33796536›Full record

ReviewFrontiers in cell and developmental biology2021

The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy.

David García-Bernal, Mariano García-Arranz, Rosa M Yáñez, Rosario Hervás-Salcedo, Alfonso Cortés, María Fernández-García, Miriam Hernando-Rodríguez, Óscar Quintana-Bustamante, Juan A Bueren, Damián García-Olmo and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 4 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

David García-BernalHematopoietic Transplant and Cellular Therapy Unit, Medicine Department, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, University of Murcia, Murcia, Spain.
Mariano García-ArranzSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Rosa M YáñezSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Rosario Hervás-SalcedoSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Alfonso CortésSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
María Fernández-GarcíaSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Miriam Hernando-RodríguezSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Óscar Quintana-BustamanteSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Juan A BuerenSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Damián García-OlmoSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Jose M MoraledaHematopoietic Transplant and Cellular Therapy Unit, Medicine Department, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, University of Murcia, Murcia, Spain.
José C SegoviaSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Agustín G ZapataSpanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Salud Carlos III · ESUniversidad Complutense de Madrid · ESHospital Universitario Fundación Jiménez Díaz · ESUniversidad Autónoma de Madrid · ESCentro de Investigaciones Energéticas, Medioambientales y Tecnológicas · ESInstituto Murciano de Investigación Biosanitaria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Although the therapeutic efficacy of these cells has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. On the other hand, diverse controversial issues on the biology and clinical applications of MSCs, including their specific phenotype, the requirement of an inflammatory environment to induce immunosuppression, the relevance of the cell dose and their administration schedule, the cell delivery route (intravascular/systemic vs. local cell delivery), and the selected cell product (i.e., use of autologous vs. allogeneic MSCs, freshly cultured vs. frozen and thawed MSCs, MSCs vs. MSC-derived extracellular vesicles, etc.) persist. In the current review article, we have addressed these issues with special emphasis in the new approaches to improve the properties and functional capabilities of MSCs after distinct cell bioengineering strategies.

Indexed as

MSC bioengineeringMSC homingMSC immunomodulationMSC preconditioningMSC therapeutic efficacy

Identifiers

PMID33796536
PMCPMC8007911
OpenAlexW3138368294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.